Pfizer Inc.'s (JOBS) Bone-Drug Fablyn Fails to Win U.S. Approval

January 17, 2009 |

1 min read

Jan. 16 (Bloomberg) -- Pfizer Inc., the world’s largest drugmaker, failed to win U.S. approval to sell a treatment for women with weak bones that may be linked to an increase in deaths.

FDA Approvals Regulatory

Pfizer

MORE ON THIS TOPIC

Finding the right balance in business. Art collage.

Regulatory

Summit’s Potential Keytruda Rival Gets November FDA Decision Date

January 30, 2026

·

1 min read

·

Tristan Manalac

Array of piggy banks in saturated colours on high colour contrast background. Illustration of the concept of bank savings, financial investment and multiple sources of income

Insights

Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026

January 29, 2026

·

3 min read

·

Jennifer Smith-Parker

Composite photo collage of business people hands hold checkered flags success finish vote competition isolated on painted background.

Rare diseases

REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval

January 28, 2026

·

2 min read

·

Dan Samorodnitsky

Pictured: J&J's office in Madrid, Spain

Cancer

J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline

January 28, 2026

·

2 min read

·

Tristan Manalac